Small-Cap Surge: Catalyst Countdown (NEHC, BREA, MGNX, BDRX, JFBR)

Every week, we explore emerging market catalysts, seeking the next small-cap poised for a breakout. Our spotlight is on five standout small-cap stocks, uncovered through key signals like resistance breakthroughs, sharp volume spikes, and consolidation trends.

New Era Helium Inc (NASDAQ: NEHC) - New Era Helium Inc. shares climbed nearly 8% last week, closing at $2.86. Earlier this month, the company finalized its previously announced business combination with Roth CHVHoldings, Inc. (Nasdaq: ROCL) and Roth CH Acquisition V Co., merging with Roth CH V Merger Sub Corp., a subsidiary of Holdings. This transaction, approved by ROCL stockholders on November 26, 2024, marks a significant milestone for New Era Helium. In addition, the company announced substantial progress on its 50/50 joint venture (JV) with Sharon AI, Inc., a leader in AI, Cloud GPU Compute, and Cloud Storage solutions. The JV plans to develop a 250MW net-zero energy data center in the Permian Basin, significantly expanding from the initially planned 90MW facility. This growth underscores increasing demand from potential off-takers and highlights the strategic importance of the Texas-based project. The initiative aligns with both companies’ dedication to clean energy and cutting-edge technologies to meet the growing demands of the data industry. Key Timeline: The joint venture agreement is expected to be finalized by December 23, 2024. Sharon AI will remain the exclusive AI/HPC provider, responsible for designing, building, and operating the high-density, liquid-cooled, Tier III data center. Leveraging partnerships with NVIDIA and Lenovo, Sharon AI will optimize the data center’s performance for AI/HPC workloads. New Era Helium will exclusively handle the energy infrastructure, including designing and constructing a gas-fired power plant, implementing CO2 carbon capture, and associated pipeline work. As updates unfold, we are eyeing a potential breakout above the $3.00 resistance level, especially with increased trading volume.

--

Brera Holdings PLC (NASDAQ: BREA) - Brera Holdings PLC shares gained 20% last week, closing at $0.78. This month, the company announced at a press conference in Naples that it has signed a binding term sheet for a strategic investment in SS Juve Stabia SpA ("Juve Stabia"), a storied Italian Serie B football club with 117 years of history. Brera’s investment aims to strengthen Juve Stabia’s competitiveness in Serie B and beyond, working alongside the Club’s current majority owner, XX Settembre srl, and Club President Andrea Langella. The transaction is structured over three phases, targeting an approximate 52-48 shareholding split between Brera and XX Settembre, with the initial closing expected by December 31, 2024, and completion by March 31, 2025. Known as "The Second Team of Naples," Juve Stabia plays a vital role in Italy’s third-largest metropolitan area, situated near the iconic landmarks of Pompeii and the Amalfi Coast. This unique combination of sporting heritage and cultural prominence enhances the Club’s strategic value. "After in-depth analysis and discussions with leading Serie B clubs, Brera Holdings is proud to invest in Juve Stabia and collaborate with President Andrea Langella," said Daniel McClory, Brera’s Executive Chairman and Founder. "Competing in the dynamic Naples metropolitan area, with its 3.5 million residents and a rich football tradition, makes this partnership particularly exciting and strategic," McClory added. As we await further updates, we will be watching for increased trading volume and a potential resistance breakout in the $0.80–$0.82 range.

--

MacroGenics, Inc. (NASDAQ: MGNX) - MacroGenics, Inc. shares ended last week flat at $3.18. Last month, the company provided an update on its corporate progress and financial results for the quarter ending September 30, 2024. According to Scott Koenig, M.D., Ph.D., President and CEO, the pending MARGENZAtransaction and a milestone payment from Incyte have strengthened the company’s financial position, enabling continued focus on advancing its pipeline of innovative product candidates. Among recent achievements, MacroGenics submitted the IND for MGC028, a topoisomerase I inhibitor-based ADC, and plans to begin a dose-escalation study in the coming months. Dr. Koenig highlighted that the company’s expanding clinical portfolio is creating opportunities for near-term data readouts. Vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate targeting B7-H3, an antigen broadly expressed across multiple solid tumors, has shown promise. Interim results from the TAMARACK study were presented at the European Society for Medical Oncology (ESMO) Congress in September 2024, with mature radiographic progression-free survival (rPFS) data expected by early 2025. Lorigerlimab, a bispecific, tetravalent PD-1 × CTLA-4 DART® molecule, is under evaluation in the ongoing LORIKEET trial. This randomized Phase 2 study compares lorigerlimab combined with docetaxel to docetaxel alone in second-line, chemotherapy-naïve mCRPC patients. With more than 100 participants enrolled, the study aims to complete enrollment by late 2024 or early 2025. The company also announced the sale of global rights for MARGENZA(margetuximab-cmkb) to TerSera Therapeutics LLC, a privately-held biopharmaceutical company. Under the agreement, TerSera will pay $40 million at closing, with additional sales milestone payments of up to $35 million possible. The deal, expected to close in the fourth quarter of 2024, includes MacroGenics continuing to manufacture the MARGENZA drug substance. An $8 million amendment fee will be paid to its current commercialization partner as part of the transaction. We will be monitoring for increased trading volume and a potential resistance breakout at $3.25 as we await further updates from the company.

--

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) - Biodexa Pharmaceuticals plc shares closed last week down less than 1% at $3.99. The company recently announced significant progress in its transformation from a drug delivery innovator to a therapeutics-focused company targeting diabetes and cancer. This strategic shift appears to be paying off, highlighted by its acquisition of eRapa, a treatment candidate for familial adenomatous polyposis (FAP). FAP is a hereditary condition that dramatically increases the risk of colon cancer, with hundreds to thousands of precancerous polyps developing throughout the gastrointestinal tract. Currently, no approved therapeutic options exist, leaving patients reliant on active surveillance and eventual surgical removal of the colon or rectum, often resulting in the need for a colostomy bag. Without treatment, FAP carries a 100% risk of developing colorectal cancer. Earlier this year, Biodexa published promising phase 2 data for eRapa. The six-month and 12-month results showed a median reduction in polyp burden of 29% and a non-progression rate of 89% for patients on the preferred dosage regimen. "In a world where most drugs slow, or at best, halt progression, these results exceeded our expectations," said Stamp. The FAP program received a $17 million grant from the Cancer Prevention Research Institute of Texas, with Biodexa fulfilling the required funding match, unlocking access to $25.5 million in total. This funding will largely support the phase 3 study through to the New Drug Application (NDA) filing, expected within three years. The next milestone is a Type C meeting with the FDA to finalize the Phase 3 protocol, with patient recruitment set to begin in early 2025. In addition to FAP, Biodexa is conducting a placebo-controlled phase 2 study of eRapa for non-muscle invasive bladder cancer (NMIBC), an early-stage form of bladder cancer. Of the 168 planned participants, approximately 130 have been enrolled, with the possibility of an interim analysis by the end of the year. As we await further updates, we will be watching for a resistance break at $4.20 or for the $3.50 support level to hold.

--

Jeffs Brands Ltd (NASDAQ: JFBR) - Jeffs Brands Ltd. shares closed last week’s trading session with a 7% increase, reaching $2.44. Earlier this month, the company revealed it had entered into a binding Letter of Intent (LOI) with Deliverz.AI Ltd. (Deliverz.AI), a company specializing in AI-powered, fully autonomous multi-purpose robotic platforms. Announced on November 27, 2024, the LOI outlines plans for a joint venture (JV) focused exclusively on the U.S. market, combining the strengths of both companies to introduce AI-driven robotics solutions for healthcare logistics. Deliverz.AI is known for its autonomous navigation platforms, such as its flagship robot Polly, which is currently used at Israel’s Sheba Medical Center (ranked 9th globally by Newsweek) to autonomously deliver chemotherapy drugs in complex hospital settings. Their AI-powered solutions are designed for seamless navigation both indoors and outdoors, optimizing workflows in healthcare, smart cities, and Industry 4.0. Under the terms of the LOI, Deliverz.AI will contribute its proprietary robotics technology and operational software to the JV in exchange for a 50% equity stake, while Jeffs Brands will invest $1 million for an equal 50% stake. The investment will be made in phases: $100,000 upon signing the definitive JV agreement, another $100,000 upon securing the JV's first U.S. pilot project, and the remaining $800,000 in installments through 2025, based on mutually agreed-upon budgets. The JV aims to partner with U.S. medical centers to deploy robotic solutions that enhance logistics efficiency and healthcare delivery. Both companies are committed to finalizing the definitive agreements within 30 days, which will include standard closing conditions, regulatory approvals, and satisfactory due diligence. Additionally, Jeffs Brands has secured an exclusive worldwide agreement to distribute advanced drone safety systems developed by a leading drone company for two years. These systems will be sold exclusively through Amazon’s global marketplace, underscoring Jeffs Brands' commitment to leveraging its e-commerce expertise to bring innovative technological solutions to consumers. (Note: The company filed for an F-3 on 12/16 but not in effect yet). As we await further updates from the company, we will be monitoring for increased trading volume and a potential breakout above the $2.65 resistance level.

Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.